P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain
- PMID: 8701997
- PMCID: PMC1865300
P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain
Abstract
The presence of beta-amyloid in brain tissue is characteristic of Alzheimer's disease (AD). A naturally occurring derivative of the beta-amyloid peptide, p3, possesses all of the structural determinants required for fibril assembly and neurotoxicity. p3-specific antibodies were used to examine the distribution of this peptide in brain. p3 reactivity was absent or sparse in aged non-AD brains but was prevalent in selected areas of AD brain in diffuse deposits and in a subset of dystrophic neurites. p3-reactive dystrophic neurites were found both independent in the neuropil and associated with plaques. Little or no reactivity was observed to amyloid cores in classical plaques or to amyloid in the cerebral vasculature. The exclusive appearance of p3 reactivity in AD brain plus the selective localization of p3 reactivity to abnormal structures in the temporal lobe limbic system suggests that p3 may be a contributing factor to AD pathology.
Similar articles
-
Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.Exp Neurol. 2004 Nov;190(1):192-203. doi: 10.1016/j.expneurol.2004.06.011. Exp Neurol. 2004. PMID: 15473992
-
Identification of a unique apolipoprotein E allele in Microcebus murinus; ApoE brain distribution and co-localization with beta-amyloid and tau proteins.Neurobiol Dis. 1995 Jun;2(3):169-76. doi: 10.1006/nbdi.1995.0018. Neurobiol Dis. 1995. PMID: 9174000
-
Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.Neurobiol Dis. 1996 Feb;3(1):16-32. doi: 10.1006/nbdi.1996.0003. Neurobiol Dis. 1996. PMID: 9173910
-
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.Science. 2002 Jul 19;297(5580):353-6. doi: 10.1126/science.1072994. Science. 2002. PMID: 12130773 Review.
-
Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?1.J Alzheimers Dis. 2020;74(1):43-53. doi: 10.3233/JAD-191201. J Alzheimers Dis. 2020. PMID: 32176648 Free PMC article. Review.
Cited by
-
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model.J Clin Invest. 2004 May;113(10):1456-64. doi: 10.1172/JCI20864. J Clin Invest. 2004. PMID: 15146243 Free PMC article.
-
Microglia in Alzheimer's disease and transgenic models. How close the fit?Am J Pathol. 1999 Jun;154(6):1627-31. doi: 10.1016/S0002-9440(10)65416-8. Am J Pathol. 1999. PMID: 10362785 Free PMC article. No abstract available.
-
The secretases: enzymes with therapeutic potential in Alzheimer disease.Nat Rev Neurol. 2010 Feb;6(2):99-107. doi: 10.1038/nrneurol.2009.218. Nat Rev Neurol. 2010. PMID: 20139999 Free PMC article. Review.
-
Integration of O-GlcNAc into Stress Response Pathways.Cells. 2022 Nov 5;11(21):3509. doi: 10.3390/cells11213509. Cells. 2022. PMID: 36359905 Free PMC article. Review.
-
Molecular interactions of Alzheimer amyloid-β oligomers with neutral and negatively charged lipid bilayers.Phys Chem Chem Phys. 2013 Jun 21;15(23):8878-89. doi: 10.1039/c3cp44448a. Epub 2013 Mar 14. Phys Chem Chem Phys. 2013. PMID: 23493873 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical